Comparative Pharmacology
Head-to-head clinical analysis: ANGELIQ versus FEMHRT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGELIQ versus FEMHRT.
ANGELIQ vs FEMHRT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angeliq combines drospirenone, a spironolactone analogue with antimineralocorticoid and antiandrogenic activity, and estradiol, an estrogen that replaces endogenous estrogen and regulates gonadotropin secretion.
FEMHRT is a combination of ethinyl estradiol and norethindrone acetate. Ethinyl estradiol is an estrogen that binds to estrogen receptors, promoting proliferation of the endometrium and other estrogen-responsive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, causing secretory changes in the endometrium and inhibiting gonadotropin release from the pituitary, thereby suppressing ovulation.
One tablet (drospirenone 0.5 mg/estradiol 1 mg) orally once daily.
One tablet (estradiol 1 mg/norethindrone acetate 0.5 mg) orally once daily
None Documented
None Documented
Estradiol: terminal half-life 13-18 hours; Drospirenone: terminal half-life 25-32 hours, allowing once-daily dosing.
Estradiol: terminal half-life approximately 24 hours due to enterohepatic recirculation. Norethindrone: terminal half-life approximately 8-11 hours.
Estradiol: renal (90%) as conjugates (glucuronide and sulfate), fecal (10%). Drospirenone: renal (50%) as inactive metabolites, fecal (50%) as metabolites; less than 1% excreted unchanged.
Estradiol: primarily renal (60-80% as conjugates, primarily glucuronides and sulfates), fecal (10-20%). Norethindrone: primarily renal (60-70% as metabolites), fecal (30-40%).
Category C
Category C
Hormone Replacement Therapy
Hormone Replacement Therapy